Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers. Its lead program centers on elraglusib, a small-molecule GSK-3 inhibitor being studied in clinical trials for advanced solid tumors and certain pediatric cancers. The company’s work is aimed at targeting cancer pathways involved in tumor growth, survival, and resistance to standard treatments. Actuate Therapeutics also explores applications in cancer types and related disease areas where conventional options remain limited, positioning it within the oncology drug development segment of the healthcare market. Headquartered in Fort Worth, Texas, Actuate Therapeutics concentrates on advancing investigational medicines through early and mid-stage development, with a business model built around translational research, clinical testing, and potential future commercialization of targeted therapies.
United States
CHICAGO and FORT WORTH, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, today announced that it will present at the H.C. Wainwright 28th Annual Global Investment Conference taking place September 14-16, 2026, in New York City. In addition, the management team will be available for one-on-one mee
Actuate Therapeutics, Inc. (ACTU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Gainers NextCure (NASDAQ:NXTC) stock increased by 201.4% to $6.57 during Tuesday's regular session. The market value of their outstanding shares is at $7.8 million. Shuttle Pharmaceuticals (NASDAQ:SHPH) shares
Gainers Agenus (NASDAQ:AGEN) shares increased by 95.8% to $6.56 during Monday's regular session. The market value of their outstanding shares is at $139.5 million. Q32 Bio (NASDAQ:QTTB) stock rose 81.08% to $20.3.
Investors talking about ACTU also mention
| # | Name | Attention |
|---|---|---|
| 1 | Q32 Bio Inc.QTTB | 0%+0 |
| 2 | Bluejay Diagnostics Inc.BJDX | 0%0 |
| 3 | ZenaTech Inc.ZENA | 0.02%+0.01 |
| 4 | Ondas Inc.ONDS | 0.31%-0.01 |
| 5 | Corvex Inc. Common StockMOVE | 0%0 |
| 6 | MKDWELL Tech Inc.MKDW | 0%+0 |
| 7 | America's Car-Mart, Inc.CRMT | 0%0 |
| 8 | Netcapital Inc. Common StockNCPL | 0.01%+0.01 |
| 9 | AEye, Inc. Class A Common StockLIDR | 0%0 |
| 10 | Brenmiller Energy LtdBNRG | 0%new |
What share of all ETF conversation is about ACTU?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% 0 | 0% 0 | 0% +0 | 0% +0 |
Of the messages about ACTU that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | — | 100% | 99.12% +3.67 | ||
| Bearish | — | — | 0% | 0.88% -3.67 |
Of the messages about ACTU that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Technical Analysis | — | — | 100% | 100% | ||
| Macro | — | — | 0% | 0% |
Of the messages about ACTU, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | — | — | 0% | 5.42% | ||
| Newcomers | — | — | 100% | 94.58% |